Palo Alto – February 13, 2015 – Cooley advised the underwriters on Nexvet Biopharma plc's initial public offering. Nexvet is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics based on human biologics. The company now trades on The Nasdaq Global Market under the symbol "NVET."
BofA Merrill Lynch and Cowen and Company are acting as joint lead book-running managers for the offering. Piper Jaffray and JMP Securities are acting as co-managers.
About Cooley LLP
Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe.